Veterinary Psychopharmacology

ISBN-13: 9781119226222 / Angielski / Twarda / 2019 / 336 str.

Sharon Crowell-Davis; Thomas Murray; Leticia Mattos de Souza Dantas

Spis treści

Contributors xxiPreface xxiiiAcknowledgments xxvPart I Principles of Veterinary Psychopharmacology 11 General Principles of Psychopharmacology 3Thomas F. MurrayDrug Action 3Dose Dependence of Drug Interaction with Receptors 4Structural Features of the Central Nervous System (CNS) and Neurotransmission 5Biogenic Amine Neurotransmitters and Affective Disorders 82 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines 11Thomas F. MurrayIntroduction 11Glutamatergic Synapses 11Pharmacology of Ketamine and Tiletamine 14GABAergic Synapses 153 Biogenic Amine Neurotransmitters: Serotonin 21Thomas F. MurrayIntroduction 21The Biogenic Amines 21Serotonin 224 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine 29Thomas F. MurrayAcetylcholine 29Norepinephrine 32Dopamine 375 Neuropeptides: Opioids and Oxytocin 43Thomas F. MurrayIntroduction 43Endogenous Opioid Peptides 43Oxytocin 47Part II Practice of Veterinary Psychopharmacology 516 Introduction to Clinical Psychopharmacology for Veterinary Medicine 53Sharon L. Crowell-Davis and Leticia Mattos de Souza DantasIntroduction 53Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) 54Cost 55Drug Selection 56Medicating the Patient 57Competition Animals 58Taking the Behavioral History 58The Behavioral Exam 63Duration of Treatment 63Limitations 647 Benzodiazepines 67Leticia Mattos de Souza Dantas and Sharon L. Crowell-DavisAction 67Overview of Indications 67Contraindications, Side Effects, and Adverse Events 69Overdose 69Clinical Guidelines 69Specific Medications 71I. Alprazolam 71II. Chlordiazepoxide HC1 73IV. Clorazepate Dipotassium 78V. Diazepam 80VI. Flurazepam Hydrochloride 86VII. Lorazepam 87VIII. Oxazepam 89IX. Triazolam 918 Selective Serotonin Reuptake Inhibitors 103Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell-DavisAction 103Overview of Indications 103Contraindications, Side Effects, and Adverse Events 104Adverse Drug Interactions 104Overdose 105Clinical Guidelines 105Specific Medications 106I. Citalopram Hydrobromide 106II. Fluoxetine Hydrochloride 108III. Fluvoxamine 115IV. Paroxetine Hydrochloride 117V. Sertraline Hydrochloride 119VI. Escitalopram Oxalate 1229 Miscellaneous Serotonergic Agents 129Leticia Mattos de Souza Dantas and Sharon L. Crowell-DavisIntroduction 129Azapirones 129Action 129Overview of Indications 129Contraindications, Side Effects, and Adverse Events 129Adverse Drug Interactions 129Overdose 129Clinical Guidelines 129Specific Medications 130I. Buspirone 130I. Trazodone Hydrochloride 13510 Anticonvulsants and Mood Stabilizers 147Sharon L. Crowell-Davis, Mami Irimajiri, and Leticia Mattos de Souza DantasAction 147Overview of Indications 148Clinical Guidelines 148Specific Medications 148I. Carbamazepine 148II. Gabapentin 149III. Pregabalin 15211 Sympatholytic Agents 157Niwako Ogata and Leticia Mattos de Souza DantasAction 157Overview of Indications 157Contraindications, Side Effects, and Adverse Events 158Overdose 159Clinical Guidelines 159Specific Medications 160I. Clonidine 160II. Detomidine 161III. Dexmedetomidine 163IV. Propranolol 16512 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists 171Niwako Ogata and Leticia Mattos de Souza DantasAction 171Overview of Indications 172Contraindications/ Side Effects, and Adverse Events 172Clinical Guidelines 173Specific Medications 173I. Dextromethorphan 173II. Amantadine 175III. Memantine 176IV. Huperzine A 17913 Monoamine Oxidase Inhibitors 185Leticia Mattos de Souza Dantas and Sharon L. Crowell-DavisAction 185Overview of Indications 186Specific Medications 186I. Selegiline Hydrochloride 18614 Antipsychotics 201Lynne Seibert and Sharon Crowell-DavisIntroduction 201Action 201Overview of Indications 202General Pharmacokinetics 203Contraindications, Side Effects, and Adverse Events 203Overdose 203Clinical Guidelines 204Specific Medications 204I. Acepromazine Maleate 204II. Azaperone 206III. Chlorpromazine 206IV. Clozapine 207V. Fluphenazine 208VI. Haloperidol 209VII. Pimozide 210VIII. Promazine 211IX. Sulpiride 211X. Thioridazine 21215 CNS Stimulants 217Sharon L. Crowell-DavisAction 217Overview of Indications 217Contraindications, Side Effects, and Adverse Events 217Adverse Drug Interactions 217Overdose 217Clinical Guidelines 218Specific Medications 219I. Amphetamine 219II. Atomoxetine HCl 221III. Methylphenidate Hydrochloride 22316 Tricyclic Antidepressants 231Sharon L. Crowell-DavisAction 231Overview of Indications 231Contraindications, Side Effects, and Adverse Events 232Adverse Drug Interactions 232Overdose 232Discontinuation 233Clinical Guidelines 233Specific Medications 233I. Amitriptyline 233II. Clomipramine Hydrochloride 236III. Desipramine 243IV. Doxepin 244V. Imipramine 246VI. Nortriptyline 24817 Opioids and Opioid Antagonists 257Leticia Mattos de Souza Dantas and Sharon L. Crowell-DavisAction 257Overview of Indications 257Contraindications, Side Effects, and Adverse Events 258Clinical Guidelines 258Specific Medications 258I. Nalmefene 258II. Naloxone HCl 260III. Naltrexone Hydrochloride 261IV. Pentazocine 26418 Hormones 269Sharon L. Crowell-DavisIntroduction 269Oxytocin 270Clinical Pharmacology 270Indications 270Side Effects 270Doses in Nonhuman Animals 270Effects Documented in Nonhuman Animals 270Progestins 270Action 270Overview of Indications 271Contraindications, Side Effects, and Adverse Events 271Overdose 271Clinical Guidelines 272Specific Medications 272I. Medroxyprogesterone Acetate (MPA) 272II. Megestrol Acetate 27319 Combinations 281Leticia Mattos de Souza Dantas, Sharon L. Crowell-Davis, and Niwako OgataIntroduction 281Overview of Drug Augmentation 281Potentially Beneficial Combinations 282Adverse Interactions and Contraindications 283Changing and Weaning Patients off Medications 285Cytochrome P450 (CYP) 285Interactions That Can Affect Dosing 285Algorithms: Possible Future Direction 286Conclusion 288Index 291

O autorze

The AuthorsThe EditorsSharon L. Crowell-Davis, DVM, PhD, DACVB, is a Professor of Behavioral Medicine in the Department of Veterinary Biosciences and Diagnostic Imaging, College of Veterinary Medicine, the University of Georgia in Athens, Georgia, USA.Thomas F. Murray, PhD, is a Professor of Pharmacology and Provost of Creighton University in Omaha, Nebraska, USA.Leticia Mattos de Souza Dantas, DVM, MS, PhD, DACVB is a Clinical Assistant Professor of Behavioral Medicine at the University of Georgia Veterinary Teaching Hospital and the Department of Veterinary Biosciences and Diagnostic Imaging at the College of Veterinary Medicine, University of Georgia in Athens, Georgia, USA. She is also the Director and Co-founder of ZooPsych, Inc., a consultancy in Clinical Behavioral Medicine & Therapy in Georgia, USA.